We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
From the FDA.
- Abstract
The article provides updates related to drug licensing approval by the U.S. Food and Drug Administration (FDA). The agency has approved Atomoxetine HCl for treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. Aplenzin from Biovail Corp. got its FDA final approval for the treatment of major depressive disorder in adults. FDA has granted an approval for aripiprazole for maintenance treatment of manic and mixed episodes associated with bipolar I disorder.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration; DRUG approval; PHARMACEUTICAL policy; BIOVAIL Corp.; TREATMENT of attention-deficit hyperactivity disorder; BIPOLAR disorder; THERAPEUTICS
- Publication
Brown University Psychopharmacology Update, 2008, Vol 19, Issue 8, p8
- ISSN
1068-5308
- Publication type
Article